Inhalation Sciences submits whitepaper to FDA aiming to establish DissolvIt® as an FDA-recommended standard research method in US
(Stockholm, 17 January 2022) Inhalation Sciences (ISAB) has submitted a white paper to the US FDA (Food and Drug Administration) aiming to validate its in vitro simulated lung model DissolvIt[®] as an FDA-recommended technology, and, ultimately, a new standard research method for inhaled drug research in the US. If approved, the FDA will co-fund the project for up to 250 KUSD (approx. 2.2 MSEK) on an annual basis for up to two years. A final decision on approval for the submitted whitepaper is expected in September 2022.Inhalation Sciences has submitted a formal whitepaper to the FDA’s